AACI Contributes to Report on Clinical Trial Enrollment
The American Cancer Society Cancer Action Network (ACS CAN) has issued a new report identifying barriers to enrolling cancer patients in clinical trials and proposing ways that they can be overcome. AACI Director of Programs Janie Hofacker, RN, BSN, MS, was a member of the steering committee that provided research, data, advice, and, in some cases, text or edits, for the report. Ms. Hofacker represented AACI in a panel discussion, "Provider and Institution Barriers to Enrollment," during the reportís release in April at the organizationís annual National Policy Forum, held at the National Press Club in Washington, DC.
ACS CAN President Christopher W. Hansen said the report goes beyond simply identifying barriers because of its recommendations for taking action. "Weíll be doing just that: taking action," he said.
"This is an unprecedented time in the cancer fight," added Gary M. Reedy, CEO of ACS and ACS CAN. Reedy said it is important to take advantage of new laboratory discoveries and get new emergent therapies into clinical trials as soon as possible.
AACI is one of 17 cancer organizations endorsing the recommendations in "Barriers to Patient Enrollment in Therapeutic Clinical Trials for Cancer - A Landscape Report."